Malignant pleural mesothelioma (MPM) is an aggressive and highly lethal cancer. Combined treatment with two cancer immunotherapy drugs significantly prolonged survival in mouse models of MPM . Recent findings from The Cancer Genome Atlas Research Network provided both a rationale and a biomarker for clinical trials of emerging anti-VISTA immunotherapies . Use of high-throughput technologies to characterise the genomic and epigenetic landscapes of mesothelioma may drive advances in novel clinical treatments .
“There are lots of needs in the surgical management of mesothelioma,” said Dr Valerie Rusch (Memorial Sloan-Kettering Cancer Center, USA). She cited many opinions, only modest amounts of data, and even less standardisation.
The minimal acceptable standards for optimal biopsy and staging are controversial, said Dr Rusch. Questions center on whether surgical biopsy (VATS) is always required and how many sites should be biopsied to account for tumour heter...
please login to read the entire article:
You need to register to read the entire article, please do so now.
« Crizotinib-treated ALK IHC-positive advanced NSCLC is associated with an unfavourable prognosis when FISH negative Next Article
Who are the high-risk patients for surgical failure in mesothelioma? »
Table of Contents: WCLC 2018
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.